CIENCIASMEDICASNEWS: FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib) | FDA

jueves, 24 de febrero de 2022

FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib) | FDA

FDA investigating possible increased risk of death with lymphoma medicine Ukoniq (umbralisib) | FDA

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)